Analysts Expect Aurora Cannabis Inc. (NYSE:ACB) to Announce -$0.18 Earnings Per Share

Brokerages expect Aurora Cannabis Inc. (NYSE:ACB) to announce earnings of ($0.18) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Aurora Cannabis’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.24). Aurora Cannabis reported earnings per share of ($0.13) in the same quarter last year, which would suggest a negative year over year growth rate of 38.5%. The company is scheduled to issue its next quarterly earnings results on Thursday, September 23rd.

According to Zacks, analysts expect that Aurora Cannabis will report full year earnings of ($2.39) per share for the current fiscal year, with EPS estimates ranging from ($2.76) to ($1.83). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.75) to ($0.29). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Aurora Cannabis.

Aurora Cannabis (NYSE:ACB) last issued its quarterly earnings data on Wednesday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.65). Aurora Cannabis had a negative return on equity of 16.32% and a negative net margin of 1,238.94%.

ACB has been the subject of several recent analyst reports. Needham & Company LLC assumed coverage on shares of Aurora Cannabis in a research note on Friday. They issued a “sell” rating for the company. Canaccord Genuity cut Aurora Cannabis from a “hold” rating to a “sell” rating and reduced their price target for the company from $14.00 to $7.00 in a report on Friday. MKM Partners cut Aurora Cannabis from a “neutral” rating to a “sell” rating in a research report on Friday, February 12th. Bank of America began coverage on shares of Aurora Cannabis in a research report on Wednesday, April 28th. They set a “neutral” rating on the stock. Finally, Desjardins downgraded shares of Aurora Cannabis from a “hold” rating to a “sell” rating in a report on Friday, February 12th. Seven research analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company. The company currently has an average rating of “Hold” and an average target price of $9.11.

Shares of ACB stock opened at $6.86 on Wednesday. The company has a current ratio of 1.88, a quick ratio of 1.07 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $8.60 and its two-hundred day moving average is $9.63. Aurora Cannabis has a twelve month low of $3.71 and a twelve month high of $19.68. The company has a market capitalization of $1.36 billion, a P/E ratio of -0.28 and a beta of 3.44.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. TD Asset Management Inc. increased its position in Aurora Cannabis by 10.8% during the 1st quarter. TD Asset Management Inc. now owns 626,824 shares of the company’s stock worth $5,830,000 after purchasing an additional 61,267 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Aurora Cannabis in the 1st quarter worth approximately $159,000. Franklin Resources Inc. boosted its holdings in Aurora Cannabis by 69.7% in the 1st quarter. Franklin Resources Inc. now owns 26,845 shares of the company’s stock worth $250,000 after acquiring an additional 11,023 shares during the period. SG Americas Securities LLC boosted its holdings in Aurora Cannabis by 9.5% in the 1st quarter. SG Americas Securities LLC now owns 40,098 shares of the company’s stock worth $373,000 after acquiring an additional 3,474 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Aurora Cannabis in the 1st quarter worth approximately $2,288,000. 11.86% of the stock is owned by hedge funds and other institutional investors.

About Aurora Cannabis

Aurora Cannabis Inc produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility engineering and design, cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Recommended Story: What are the risks of holding treasury bonds?

Get a free copy of the Zacks research report on Aurora Cannabis (ACB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.